ArticleESC heart failure2024

Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF.

Nicklas Bergh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.